Antibodies from dogs with canine visceral leishmaniasis recognise two proteins from the saliva of Lutzomyia longipalpis
- 137 Downloads
The saliva of the sand fly Lutzomyia longipalpis, a major vector of Leishmania, exhibits pharmacological and immunomodulatory activities that may facilitate entry and establishment of parasites into the vertebrate host. Salivary gland components of the sand fly are, therefore, potential candidates in the development of a vaccine against human leishmaniasis. With the objective of identifying sand fly saliva proteins that could be used to immunise animals against canine visceral leishmaniasis, we have evaluated anti-saliva antibody reactivity using serum samples collected from dogs naturally infected with Leishmania chagasi. Two proteins with molecular weights of 28.6 and 47.3 kDa were recognised by dog antibodies in Western blot assays. Protein bands were excised from an SDS-PAGE gel and the sequences determined by mass spectrometry. The proteins were identified as LuLo-D7 and Lulo YELLOW, respectively. The significance of these findings in the context of the development of multi-component vaccination experiments is discussed.
We are grateful to Leila Alves Campus for her technical assistance. This work was supported by the CNPq/BR/Grant: 541521124/98-0, FAPEMIG/BR/Grants: CBS 2222/97 (ABR) and CBB 174/02 (DB); PDTIS (Fiocruz) and FAPERJ (Rede Proteômica do Rio de Janeiro). DB was a recipient of CNPq and FAPESP fellowships. The experiments described in this study were carried out in full accordance with all pertinent laws and codes of practice applicable in Brazil.
- Gomes RB, Brodskyn C, de Oliveira CI, Costa J, Miranda JC, Caldas A, Valenzuela JG, Barral-Netto M, Barral A (2002) Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayed-type hypersensitivity. J Infect Dis 186:1530–1534PubMedCrossRefGoogle Scholar
- Laison R, Shaw JJ (1987) Evolution, classification and geographical distribution. In: Peters W, Killick-Dendrick R. The leishmaniasis in biology and medicine. Academic, London, 1–20Google Scholar
- Mohebali M, Khamesipour A, Mobedi I, Zarei Z, Hashemi-Fesharki R (2004) Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 22:4097–4100PubMedCrossRefGoogle Scholar
- Reis AB, Martins-Filho OA, Teixeira-Carvalho A, Carvalho MG, Mayrink W, Franca-Silva JC, Giunchetti RC, Genaro O, Correa-Oliveira R (2006) Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res Vet Sci 81:68–75PubMedCrossRefGoogle Scholar
- Sambrook J, Russel DW (2001) Molecular cloning: a laboratory manual, 3rd edn, vol 3. Cold Spring Harbor Laboratory Press, Cold Spring HarborGoogle Scholar
- World Health Organisation (2000) Leishmania/HIV co-infection South-Western Europe 1990–1998: retrospective analysis of 965 cases. WHO/LEISH/2000, Geneva (http://whqlibdoc.who.int/hq/2000/WHO_LEISH_2000.42.pdf)